Intellipharmaceutics International Inc (IPCI)

0.140
-0.005(-3.45%)
  • Volume:
    2,500
  • Bid/Ask:
    0.140/0.165
  • Day's Range:
    0.140 - 0.140
  • Type:Equity
  • Market:Canada
  • ISIN:CA4581733090
  • CUSIP:458173309

IPCI Overview

Prev. Close
0.145
Day's Range
0.14-0.14
Revenue
101.08K
Open
0.14
52 wk Range
0.11-0.39
EPS
-0.19
Volume
2,500
Market Cap
4.63M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
11,049
P/E Ratio
-
Beta
1.24
1-Year Change
-39.13%
Shares Outstanding
33,092,665
Next Earnings Date
Jul 13, 2022
What is your sentiment on Intellipharmaceutics?
or
Market is currently closed. Voting is open during market hours.

Intellipharmaceutics International Inc News

Intellipharmaceutics International Inc Analysis

Intellipharmaceutics International Inc Company Profile

Intellipharmaceutics International Inc Company Profile

Employees
11
Market
Canada

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • looking good for approval
    0
    • looking good for approval
      0